Eledon Pharmaceuticals GAAP EPS of -$0.52 beats by $0.15

* Eledon Pharmaceuticals press release [https://seekingalpha.com/pr/20445666-eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-operating-and-financial] (ELDN [https://seekingalpha.com/symbol/ELDN]): FY GAAP EPS of -$0.52 beats by $0.15.
* Cash, cash equivalents, and short-term investments totaled $133.33 million as of FY 2025  compared to $140.18 million as of FY 2024.

MORE ON ELEDON PHARMACEUTICALS

* Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative [https://seekingalpha.com/article/4882820-eledon-pharmaceuticals-tegoprubart-continues-to-shine-as-immunosuppressive-alternative]
* Eledon Pharma rises on FDA orphan status for lead asset [https://seekingalpha.com/news/4562680-eledon-pharma-wins-fda-orphan-status-lead-asset]
* Seeking Alpha’s Quant Rating on Eledon Pharmaceuticals [https://seekingalpha.com/symbol/ELDN/ratings/quant-ratings]
* Historical earnings data for Eledon Pharmaceuticals [https://seekingalpha.com/symbol/ELDN/earnings]
* Financial information for Eledon Pharmaceuticals [https://seekingalpha.com/symbol/ELDN/income-statement]